IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 16, 2025.

Revenue declinedEBITDA margin compressionRelated-party transactionsResults View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹80.65

prior close

₹81.45

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%-0.3% vs market

Pharmaceuticals peers, median of 150sector+1.0%-0.1% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.4

15m

-1.9

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9+1.2-0.3+1.0-0.1

Next day

-1.2+0.1-1.3-0.2-1.0

+7.3+0.9+6.4+0.5+6.7

+6.8+0.8+6.0+0.1+6.7

+6.9+1.4+5.5+0.1+6.8

+8.2+2.0+6.2+0.5+7.7

+8.9+2.3+6.6+1.5+7.4

15d

+10.4+5.2+5.2+1.4+8.9

+3.0+1.6+1.4-1.5+4.4

+21.6+7.7+13.9+3.5+18.1

+20.8+4.0+16.8-0.5+21.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved audited standalone and consolidated financial results for Q4 and FY25, along with an unmodified (clean) auditor's opinion from Ashwani & Associates. Full-year FY25 revenue from operations came in at Rs 2,079.21 crore, down about 2.5% from Rs 2,132.79 crore in FY24. Net profit for FY25 dropped roughly 25% to Rs 101 crore from Rs 135.42 crore, with EPS at Rs 3.44 versus Rs 4.61. The Q4 quarter itself was stronger, with revenue up about 4.7% year-on-year at Rs 527.78 crore and profit after tax rising to Rs 31.62 crore. The board also approved the re-appointment of Mr Vikas Gupta as Joint Managing Director for 5 years (he is the son of Managing Director Mr Varinder Gupta and brother of Executive Director Mr Abhiraj Gupta, making this a related-party appointment subject to shareholder approval) and set the 38th AGM for 22 August 2025.

Likely market impact

Mixed bag for shareholders: full-year numbers weakened on both revenue and profit, and margins clearly compressed, but the Q4 rebound suggests recovery momentum. The related-party JMD re-appointment is routine for a family-run promoter company but will require shareholder vote at the upcoming AGM.